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Abstract 
 
Background: Myc promoter-binding protein-1 (MBP-1, 37 kDa), product of alternative translation of ENO1 
mRNA, acts as a transcriptional repressor of c-MYC, ERBB2 and COX2 genes (1-3). Exogenous MBP-1 
expression suppresses proliferation and induces apoptosis in several cancer cell lines (4, 5). In infiltrating 
ductal carcinoma (IDC), loss of MBP-1 nuclear expression significantly correlates with adverse outcome, 
suggesting MBP-1 as a novel valuable histochemical marker with potential prognostic value in breast cancer 
(6). In prostate cancer cells, MBP-1 upregulates hsa-miR-29b expression, which inhibits the translation of 
anti-apoptotic and pro-metastatic proteins (7). MicroRNAs (miRNAs) are a large class of small non-coding 
RNAs that post-transcriptionally negatively regulate gene expression (8). Numerous studies have shown that 
miRNAs are involved in the regulation of different biological processes, such as cell proliferation and 
apoptosis (9). To date, observations of relationship between MBP-1 protein expression and miRNAs in 
breast cancer have not been undertaken.  
Finally, no data are available about α-enolase and MBP-1 relative expression and subcellular localization in 
other gyneacological tumors, including ovarian cancer.  
  
Methods: A preliminary in silico study was performed to hypothesize the existence of a relationship 
between the expression of MBP-1 protein and hsa-miR-29b in breast cancer. Subsequently, expression levels 
of hsa-miR-29b were assessed by q-RT-PCR, in vivo, in MBP-1
+ve
 and MBP-1
-ve
  non metastatic infiltrating 
ductal carcinomas (IDCs) and, in vitro, in SKBR-3 cells, overexpressing MBP-1. To further investigate the 
existence of a relationship between  MBP-1 and other miRNAs, a microarray analysis was conducted in vitro 
on SKBR-3 cells relative to MBP-1 protein expression and microarray results were validated by q-RT-PCR. 
miRNAs expression data were also integrated with mRNAs expression profiles.  
To evaluate the expression and subcellular localization of α-enolase and MBP-1 protein in ovarian normal 
and both primary and metastatic tumor tissues, a preliminary immunohistochemical study was performed 
using ovarian Tissues Microarrays (TMAs).  
 
Results: Bioinformatic analysis has shown that infiltrating ductal carcinomas are characterized by a 
considerable variability in the expression of hsa-miR-29b and to date no significant association of hsa-miR-
29b with the clinicopathological characteristics of breast tumors has been observed. Hsa-miR-29b target 
genes are differentially expressed in MBP-1
+ve
 and MBP-1
-ve
 IDC and these genes act  in regulatory 
networks, which include adhesion and cell migration. However, q-RT-PCR of hsa-miR-29b in vivo and in 
vitro has not allowed to assign a significant relationship  between  hsa-miR-29b and MBP-1 in breast cancer. 
Microarray analysis, in SKBR-3 cells, have shown that MBP-1 regulates both miRNAs and mRNAs 
expression involved in regulation of cell proliferation, cell migration and apoptosis.  
Tissue Microarrays have revealed that  both α-enolase and MBP-1 are expressed in normal ovarian tissues 
while their expression in tumor tissues is variable. Further analysis are necessary to correlate α-enolase 
and/or MBP-1 expression with clinicopathological characteristics of the ovarian cancers analyzed.  
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